KALV
KalVista Pharmaceuticals, Inc. · Healthcare
Insiders sold $5.8M net in the last 90 days ·6 sellers, 0 buyers· latest Form 4 filed May 29, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7.1M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Latest filing
Jun 11, 2026
Yea Christopher
KalVista Pharmaceuticals, Inc. (KALV) has 44 SEC Form 4 filings (91 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jun 11, 2026.
Inside the rolling window, 6 insiders at KalVista Pharmaceuticals, Inc. reported no open-market purchases and 39 open-market sales totaling $7.1M. The most active filer is CHIEF EXECUTIVE OFFICER Palleiko Benjamin L with 12 filings. Insiders have net sold $6.4M over the trailing 6 months. The most recent open-market filing is a sale of 33,800 shares by CHIEF DEVELOPMENT OFFICER Yea Christopher, dated May 27, 2026, worth $905K.
- Industry:Biotechnology
- CEO:Benjamin L. Palleiko
- Employees:275
- HQ:Framingham, MA, US
- IPO:2015-04-09
| Source | |||||||
|---|---|---|---|---|---|---|---|
| CHIEF DEVELOPMENT OFFICER | Sale | 33,800 | $905K | May 29 | +0.5% | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 1,966 | $53K | May 27 | +0.8% | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,489 | $40K | May 27 | +0.8% | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,239 | $60K | May 27 | +0.8% | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 10,926 | $293K | May 26 | +0.7% | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,861 | $50K | May 26 | +0.7% | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 2,358 | $63K | May 26 | +0.7% | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,685 | $72K | May 26 | +0.7% | SEC ↗ | |
| Chief Financial Officer | Sale | 1,489 | $40K | May 26 | +0.7% | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 1,108 | $30K | May 19 | +0.9% | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 1,032 | $28K | May 19 | — | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 1,129 | $30K | May 19 | — | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 3,322 | $89K | May 13 | — | SEC ↗ | |
| Chief Commercial Officer | Sale | 1,862 | $38K | Apr 20 | — | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 2,686 | $54K | Apr 20 | — | SEC ↗ | |
| Chief Financial Officer | Sale | 1,862 | $38K | Apr 20 | — | SEC ↗ | |
| CHIEF EXECUTIVE OFFICER | Sale | 9,550 | $193K | Apr 20 | — | SEC ↗ | |
Venrock Healthcare Capital Partners III, L.P.First filing | 10% Owner | Sale | 174,645 | $3.0M | Mar 27 | — | SEC ↗ |
Venrock Healthcare Capital Partners III, L.P.First filing | 10% Owner | Sale | 39,986 | $731K | Mar 27 | — | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 6,693 | $108K | Mar 10 | — | SEC ↗ | |
| CHIEF DEVELOPMENT OFFICER | Sale | 4,347 | $68K | Feb 24 | — | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,354 | $83K | Feb 24 | — | SEC ↗ | |
| Chief Commercial Officer | Sale | 3,975 | $62K | Feb 24 | — | SEC ↗ | |
Piekos BrianFirst in 3 months | Chief Financial Officer | Sale | 1,767 | $28K | Feb 24 | — | SEC ↗ |
| CHIEF EXECUTIVE OFFICER | Sale | 10,034 | $156K | Feb 24 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading KALV 1 all-time
- RRep. Chris JacobsPurchase$1,001 - $15,0002022-12-12
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does KALV have?
KalVista Pharmaceuticals, Inc. (KALV) has 44 SEC Form 4 filings (91 transaction rows) in the rolling 365-day window, disclosed by 6 distinct insiders. Most recent filing: Jun 11, 2026.
When was the most recent SEC Form 4 filing for KALV?
The most recent Form 4 filing for KALV on Tracefour is dated Jun 11, 2026.
Who is the most active insider at KALV?
The most active SEC Form 4 filer at KALV in the rolling window is CHIEF EXECUTIVE OFFICER Palleiko Benjamin L, with 12 filings.
What is the net insider flow at KALV over the last 6 months?
Over the trailing 180 days, insiders at KALV have net sold $6.4M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KALV in the current window?
Inside the rolling window, insiders at KALV bought $0 and sold $7.1M based on SEC Form 4 filings.
Can I get alerts for KALV insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at KalVista Pharmaceuticals, Inc. (KALV). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
KalVista Pharmaceuticals, Inc. is in the Healthcare sector.